Topical Ruxolitinib for Pyoderma Gangrenosum
(TRIUMPH Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a single-center, open-label, single-arm pilot study evaluating topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition that causes painful ulcers. Approximately 12 participants will apply ruxolitinib cream twice daily for 24 weeks while continuing standard wound care, with the goal of determining whether the drug helps target ulcers heal completely without the need for systemic immunosuppressive therapy. Participants will be followed for a total of 28 weeks, with the option to continue treatment in a 48-week open-label extension if they respond well and remain safe on the drug. The study is sponsored by Oregon Health \& Science University and funded by Incyte Corporation.
Are You a Good Fit for This Trial?
This trial is for adults (18-99) with a confirmed diagnosis of pyoderma gangrenosum and at least one ulcer no larger than 10 cm². Participants must be able to follow study procedures, use reliable birth control if needed, and can continue certain stable medications but not strong immunosuppressants or other JAK inhibitors.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- topical ruxolitinib
Trial Overview
The study tests ruxolitinib cream (1.5%) applied twice daily for up to 24 weeks on skin ulcers caused by pyoderma gangrenosum, alongside standard wound care. All participants receive the same treatment in this single-arm pilot study.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Treated with topical ruxolitinib thin laywer twice daily for 24 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oregon Health and Science University
Lead Sponsor
Incyte Corporation
Industry Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.